Bellevue Group AG Purchases 581 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

Bellevue Group AG raised its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 13.8% in the third quarter, Holdings Channel reports. The firm owned 4,779 shares of the company’s stock after acquiring an additional 581 shares during the quarter. Bellevue Group AG’s holdings in Krystal Biotech were worth $870,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the company. CANADA LIFE ASSURANCE Co increased its position in shares of Krystal Biotech by 80.7% during the first quarter. CANADA LIFE ASSURANCE Co now owns 3,128 shares of the company’s stock valued at $557,000 after acquiring an additional 1,397 shares in the last quarter. GAMMA Investing LLC boosted its stake in Krystal Biotech by 160.3% during the 2nd quarter. GAMMA Investing LLC now owns 151 shares of the company’s stock valued at $28,000 after purchasing an additional 93 shares during the last quarter. Jamison Private Wealth Management Inc. bought a new stake in shares of Krystal Biotech in the 2nd quarter worth $28,000. AlphaMark Advisors LLC purchased a new position in shares of Krystal Biotech in the second quarter worth $353,000. Finally, Blue Trust Inc. lifted its holdings in shares of Krystal Biotech by 2,328.6% during the second quarter. Blue Trust Inc. now owns 170 shares of the company’s stock valued at $30,000 after purchasing an additional 163 shares in the last quarter. 86.29% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms recently commented on KRYS. HC Wainwright reiterated a “buy” rating and issued a $221.00 price objective on shares of Krystal Biotech in a report on Tuesday, November 5th. Citigroup lifted their price target on shares of Krystal Biotech from $204.00 to $206.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. Chardan Capital boosted their price objective on shares of Krystal Biotech from $153.00 to $208.00 and gave the company a “buy” rating in a report on Monday, August 5th. Evercore ISI raised their target price on shares of Krystal Biotech from $201.00 to $206.00 and gave the stock an “outperform” rating in a report on Monday, August 12th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Krystal Biotech in a report on Thursday, August 29th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Krystal Biotech has an average rating of “Buy” and an average target price of $202.29.

Insiders Place Their Bets

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the transaction, the insider now owns 1,500,882 shares of the company’s stock, valued at $296,814,424.32. The trade was a 1.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 14.10% of the company’s stock.

Krystal Biotech Trading Up 0.3 %

Shares of NASDAQ KRYS opened at $197.42 on Monday. Krystal Biotech, Inc. has a 12-month low of $100.78 and a 12-month high of $219.34. The firm has a market capitalization of $5.68 billion, a price-to-earnings ratio of 111.54 and a beta of 0.82. The firm has a 50 day moving average of $180.49 and a 200 day moving average of $183.89.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings data on Monday, November 4th. The company reported $0.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.84 by $0.07. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The firm had revenue of $83.84 million during the quarter, compared to the consensus estimate of $82.94 million. During the same quarter in the previous year, the firm posted ($0.67) EPS. The company’s revenue for the quarter was up 879.9% compared to the same quarter last year. Sell-side analysts predict that Krystal Biotech, Inc. will post 2.97 EPS for the current year.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).